HealthSignals coverage organized by therapeutic area: oncology, cardio-metabolic disease, rare and genetic diseases, neuroscience, immunology and infectious diseases across Latin America and the United States.
Positive Phase 2b results for elecoglipron and aleniglipron confirm that small-molecule oral GLP-1 receptor agonists can deliver meaningful weight loss without food or fluid restrictions, intensifying competition in obesity and …
CVS Caremark will cover Eli Lilly’s oral GLP-1 pill Foundayo from June 1 and restore Zepbound as a preferred option by October 1, completing Lilly’s access across all three major …
Anvisa has granted Eurofarma the first generic registration for the dapagliflozin-metformin fixed-dose combination, mandating a minimum 35% price discount versus AstraZeneca’s Xigduo XR under Generic Law 9.787/1999.
ANS has added a PARP inhibitor for BRCA1/2-positive metastatic castration-resistant prostate cancer to Brazil’s mandatory private insurance coverage list, effective July 1, 2026, following public consultation.
WHO declared a Public Health Emergency of International Concern on May 16 after 246 suspected cases and 80 deaths in DRC’s Ituri province. Bundibugyo species has no approved countermeasures.
Medtronic’s $650M bid for SPR Therapeutics brings the FDA-cleared SPRINT Peripheral Nerve Stimulation System into its portfolio, offering a 60-day, non-permanent pain therapy backed by 6,100-patient real-world data showing 71% …
ANVISA approved BridgeBio’s acoramidis on May 6 for ATTR-CM in an all-comers indication, citing ATTRibute-CM data showing 42% reduction in all-cause mortality and cardiovascular hospitalizations at 30 months.
Biogen reports $2.5B Q1 revenue, +2% YoY, with non-GAAP EPS of $3.57, up 18%. LEQEMBI’s 78% 18-month persistence rate and a new high-dose SPINRAZA FDA approval signal commercial and pipeline …
Law 15.385/2026 mandates SUS incorporation of CONITEC-approved oncology drugs while a Fiocruz-MSD partnership delivers 100% domestically produced pembrolizumab, reducing Brazil’s import dependence for a flagship immunotherapy.
Mendoza becomes the first Argentine province to screen newborns for spinal muscular atrophy at birth, enabling pre-symptomatic treatment under a public-private accord with Novartis effective May 24, 2026.
You must be logged in to post a comment.